Kuo S, et al. - Using the Michigan Model for Diabetes (a validated computer simulation model) and published data from the EMPA-REG OUTCOME trial, researchers explored whether the favorable impact of empagliflozin on cardiovascular outcomes (CVOs) is because of its effect on multiple cardiometabolic risk factors (CRFs). In the EMPA-REG OUTCOME trial, the impact of empagliflozin on many CRFs account for some, but not all, of the reduced risks of CVOs. They suggested that more comparable control of established CRFs in type 2 diabetes CVO trials of antidiabetic agents with pleiotropic effects would facilitate the interpretation of the observed outcomes.